Livia
Wearable Device for Menstrual Pain
Company Overview
Snapshot
Founded in April 2015 by Chen Nachum, Livia operates with 1–10 employees. The company has raised $6 million across 5 funding rounds from 2 investors.
Business overview
Livia, operating under iPulse Medical, is a fem-tech brand focused on providing drug-free solutions for menstrual pain relief. Its core product, Livia, is a wearable medical device utilizing patented SmartWave™ Pain-Blocking Technology to deliver gentle electric micro-pulses, which activate the body’s natural pain-blocking mechanisms. This technology aims to provide relief within 30–60 seconds, offering a portable, discreet, and reusable alternative to traditional pain medication, without associated side effects or tolerance buildup. The company serves the health tech and life sciences sector, specifically targeting women's health and gynecology with its digital therapeutics and wearable solutions.
Strategic signal
In March 2026, Livia completed a funding round, signaling continued investor confidence in its drug-free menstrual pain relief technology. This recent capital infusion suggests the company is well-positioned to further develop and expand the reach of its wearable device, reinforcing its market presence in the fem-tech and digital therapeutics sectors.
Company Intelligence Q&A
- What is Livia's primary product?
- Livia's primary product is a wearable medical device designed to provide drug-free relief for menstrual pain, utilizing patented SmartWave™ Pain-Blocking Technology.
- When was Livia founded and by whom?
- Livia was founded in April 2015 by Chen Nachum.
- What was Livia's most recent funding activity?
- This was a private equity funding round, and the company's funding type was equity crowdfunding.
- Which investor participated in Livia's June 2022 funding round?
- In June 2022, SIBF VC participated in Livia's A Round funding, which was a private equity funding round.
- What regulatory approvals does Livia's device have?
- Livia's device is clinically proven and has received approvals from the FDA, CE, and Health Canada.